



SAFETY DATA SHEET

Revision date: 19-Mar-2015

Version: 4.0

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Diflucan (fluconazole) tablets

Trade Name: DIFLUCAN

Chemical Family: Synthetic class of compounds known as bis-triazoles

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antifungal agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Acute Oral Toxicity: Category 4

Reproductive Toxicity: Category 1B

Effects on or via lactation

Acute aquatic toxicity: Category 3

Chronic aquatic toxicity: Category 3

EU Classification:

EU Indication of danger: Harmful

Toxic to reproduction, Category 2

EU Risk Phrases:

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child.

R64- May cause harm to breastfed babies.

R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Label Elements

Signal Word: Danger

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
Revision date: 19-Mar-2015

Page 2 of 10
Version: 4.0

2. HAZARDS IDENTIFICATION

Hazard Statements:
 H302 - Harmful if swallowed
 H360D - May damage the unborn child
 H362 - May cause harm to breast-fed children
 H402 - Harmful to aquatic life
 H412 - Harmful to aquatic life with long lasting effects

Precautionary Statements:
 P202 - Do not handle until all safety precautions have been read and understood
 P264 - Wash hands thoroughly after handling
 P270 - Do not eat, drink or smoke when using this product
 P273 - Avoid release to the environment
 P281 - Use personal protective equipment as required
 P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell
 P308 + P313 - IF exposed or concerned: Get medical attention/advice
 P330 - Rinse mouth
 P405 - Store locked up
 P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards
Australian Hazard Classification (NOHSC):
 No data available
 Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Fluconazole	86386-73-4	Not Listed	Xn;R22 Repr.Cat.2;R61 R64 R52/53	Acute Tox. 4(H302) Repr. 1B (H360D) Lact. (H362) Aquatic Acute 3 (H402) Aquatic Chronic 3 (H412)	45.5
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	Not Listed	*

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
Revision date: 19-Mar-2015

Page 3 of 10
Version: 4.0

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
FD & C Red No. 40, aluminum lake	68583-95-9	271-524-7	Not Listed	Not Listed	*
Calcium phosphate dibasic, anhydrous	7757-93-9	231-826-1	Not Listed	Not Listed	*
Croscarmellose sodium	74811-65-7	Not Listed	Not Listed	Not Listed	*
Povidone	9003-39-8	Not Listed	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Carbon monoxide, carbon dioxide, nitrogen oxides and fluorine-containing compounds

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
Revision date: 19-Mar-2015

Page 4 of 10
Version: 4.0

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Calcium phosphate dibasic, anhydrous

Latvia OEL - TWA 10 mg/m³

Fluconazole

Pfizer OEL TWA-8 Hr: 500µg/m³

Magnesium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³

Lithuania OEL - TWA 5 mg/m³

Sweden OEL - TWAs 5 mg/m³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA) 10 mg/m³

Australia TWA 10 mg/m³

Belgium OEL - TWA 10 mg/m³

Estonia OEL - TWA 10 mg/m³

France OEL - TWA 10 mg/m³

Ireland OEL - TWAs 10 mg/m³

4 mg/m³

Latvia OEL - TWA 2 mg/m³

OSHA - Final PELs - TWAs: 15 mg/m³

Portugal OEL - TWA 10 mg/m³

Romania OEL - TWA 10 mg/m³

Russia OEL - TWA 6 mg/m³

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
Revision date: 19-Mar-2015

Page 5 of 10
Version: 4.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³
Vietnam OEL - TWAs	10 mg/m ³
	5 mg/m ³

Analytical Method:	Analytical method available for Fluconazole. Contact Pfizer Inc for further information.
Exposure Controls	
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablet	Color:	Pink
Odor:	Odorless	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Croscarmellose sodium

No data available

Calcium phosphate dibasic, anhydrous

No data available

Povidone

No data available

FD & C Red No. 40, aluminum lake

No data available

Microcrystalline cellulose

No data available

Magnesium stearate

No data available

Fluconazole

Predicted Log P 5.0

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
Revision date: 19-Mar-2015

Page 6 of 10
Version: 4.0

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on liver.
Known Clinical Effects:	Adverse effects most commonly reported in clinical use include skin rash, headache, nausea, and abdominal pain. Rare cases of serious liver damage and allergic reactions have been reported. There have been reports of multiple congenital abnormalities in infants whose mothers were being treated for 3 or more months with high dose (400-800mg/day) fluconazole. Fluconazole is found in human breast milk at concentrations similar to plasma. Therefore, nursing mothers should limit exposure.

Acute Toxicity: (Species, Route, End Point, Dose)

Povidone

Rat Oral LD50 100 g/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Fluconazole

Rat (F) Oral LD50 1575 mg/kg
Rat (M) Oral LD50 1325mg/kg
Mouse Oral LD50 1410mg/kg
Mouse (M) Oral LD50 1520mg/kg
Dog Intravenous LD50 > 100mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
Revision date: 19-Mar-2015

Page 7 of 10
Version: 4.0

11. TOXICOLOGICAL INFORMATION

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Fluconazole

3 Month(s)	Rat	Oral 5 mg/kg/day	NOAEL	Liver
6 Month(s)	Dog	Oral 7.5 mg/kg/day	NOAEL	Liver
12 Month(s)	Rat	Oral 10 mg/kg/day	LOAEL	Liver
12 Month(s)	Dog	Oral 2.5 mg/kg/day	NOAEL	Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Fluconazole

Reproductive & Fertility	Rat	Oral 20 mg/kg/day	NOAEL	Negative
Embryo / Fetal Development	Rabbit	Oral 20 mg/kg/day	NOAEL	Maternal Toxicity, Not Teratogenic
Embryo / Fetal Development	Rat	Oral 5 mg/kg/day	NOAEL	Fetotoxicity, Maternal Toxicity
Embryo / Fetal Development	Rat	Oral 80 mg/kg/day	LOAEL	Maternal Toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Fluconazole

<i>In Vitro</i> Bacterial Mutagenicity (Ames)	<i>Salmonella</i> , <i>E. coli</i>	Negative
<i>In Vivo</i> Cytogenetics	Mouse Bone Marrow	Negative
<i>In Vitro</i> Cytogenetics	Human Lymphocytes	Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Fluconazole

24 Month(s)	Rat Female	Oral 10 mg/kg/day	NOAEL	Not carcinogenic
24 Month(s)	Rat Female	Oral 5 mg/kg/day	LOEL	Benign tumors, Liver
24 Month(s)	Mouse	Oral 10 mg/kg/day	NOEL	Not carcinogenic

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Povidone

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:

The environmental characteristics of this mixture have not been fully evaluated. Harmful effects to aquatic organisms could occur. Releases to the environment should be avoided.

Toxicity:

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
Revision date: 19-Mar-2015

Page 8 of 10
Version: 4.0

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Fluconazole

Daphnia magna (Water Flea) LC50 48 Hours 35 mg/L

Pimephales promelas (Fathead Minnow) LC50 > 50 mg/L

Cyprinodon variegatus (Sheepshead Minnow) LC50 > 50 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability: No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Fluconazole

Predicted Log P 5.0

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
 Revision date: 19-Mar-2015

Page 9 of 10
 Version: 4.0

15. REGULATORY INFORMATION



FD & C Red No. 40, aluminum lake	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	271-524-7
Calcium phosphate dibasic, anhydrous	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-826-1
Croscarmellose sodium	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Fluconazole	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3 Schedule 4
EU EINECS/ELINCS List	Not Listed
Magnesium stearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3
Povidone	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Microcrystalline cellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Diflucan (fluconazole) tablets
Revision date: 19-Mar-2015

Page 10 of 10
Version: 4.0

15. REGULATORY INFORMATION

REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 9[f]. powder
EU EINECS/ELINCS List	232-674-9

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children
Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects

Toxic to Reproduction: Category 2
Xn - Harmful

R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.
R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 7 - Handling and Storage. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information.

Revision date: 19-Mar-2015

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet